Clinical Trials
217
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (142 trials with phase data)• Click on a phase to view related trials
Effects of Soluble Fiber Supplements on Sperm Quality in Males With Obesity: a Randomized Trial
- Conditions
- Obesity-related Poor Sperm QualityGut Microbiota
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 100
- Registration Number
- NCT07112248
CEH-EUS for Differentiating GISTs and Leiomyomas: A Multicenter Prospective Self-Controlled Study
- Conditions
- Submucosal TumorGastrointestinal Stromal Tumor (GIST)Leiomyoma
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 288
- Registration Number
- NCT07106411
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-25
- Last Posted Date
- 2025-07-25
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 40
- Registration Number
- NCT07085962
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, HUST, Wuhan, Hubei, China
Multicenter Observational Study of Multimodal AI for Upper GI Mesenchymal Tumor Diagnosis
- Conditions
- Submucosal TumorGastrointestinal Stromal Tumor (GIST)LeiomyomaSchwannoma
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-31
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 130
- Registration Number
- NCT07078136
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Cofrogliptin Once Every 2 Weeks as Add-on Therapy to Metformin and Dapagliflozin Versus Daily Linagliptin in Patients With Type 2 Diabetes.
- Conditions
- T2DM
- Interventions
- Drug: SGLT2i+Metformin+CofrogliptinDrug: SGLT2i+Metformin+Linagliptin
- First Posted Date
- 2025-06-13
- Last Posted Date
- 2025-06-13
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 170
- Registration Number
- NCT07019012
- Locations
- 🇨🇳
Wuhan University People's Hospital, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 44
- Next
News
Neoadjuvant SCRT Plus Camrelizumab Shows Promising 3-Year Survival in Locally Advanced Rectal Cancer
A phase 2 trial demonstrated that neoadjuvant short-course radiotherapy followed by camrelizumab and CAPOX chemotherapy achieved an 80.2% three-year disease-free survival rate in locally advanced rectal cancer patients.
Gene-Edited Pig Kidney Functions in Macaque for Over Six Months in Chinese Study
Chinese scientists achieved a breakthrough by maintaining a gene-edited pig kidney's function in a macaque for 184 days, marking progress in xenotransplantation.